This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hamdy, F. C. Articles by Robson, C. N. Search for Related Content PubMed PubMed Citation Articles by Hamdy, F. C. Articles by Robson, C. N.

Immunolocalization and Messenger RNA Expression of Bone Morphogenetic Protein-6 in Human Benign and Malignant Prostatic Tissue

Departments of Surgery [F. C. H., P. A., D. E. N., C. N. R.] and Pathology [C. H. W. H.], University of Newcastle. The Medical School, Newcastle upon Tyne NE2 4HH, and Department of Pathology, Freeman Hospital, Newcastle upon Tyne NE7 7DN [M. C. R.], United Kingdom

Skeletal metastases are common in advanced prostate cancer, causing considerable morbidity, and they are usually osteoblastic in nature with no clear explanation for this phenomenon. Bone morphogenetic proteins (BMPs) induce bone formation in vivo, and preliminary work showed a possible association between BMPs and prostatic skeletal metastases; differential expression favors BMP-6 as a potential new marker and mediator of osteosclerotic deposit formation. We investigated BMP-6 mRNA and protein expression by in situ hybridization and immunohistochemistry in malignant and benign prostates from 40 men. BMP-6 mRNA expression was detected exclusively in malignant epithelial cells in 20 of 21 patients (95%) with metastases and in 2 of 11 patients (18%) with localized cancer, and it was absent in 8 benign samples. Immunostaining for BMP-6 was predominantly cytoplasmic and was present in all primary tumors with established metastases and in 4 of 11 (36%) organ-confined cancers. In benign prostatic hyperplasia, basal cells and areas of basal cell hyperplasia were positive for BMP-6 by immunohistochemistry. The results suggest a close association between BMP-6 expression in primary malignant prostatic tissue and skeletal metastases. BMP-6 may be responsible, in part, for the osteoblastic changes in metastatic lesions secondary to prostate cancer.

¹ To whom requests for reprints should be addressed, at University Urology Unit, Freeman Hospital, Newcastle upon Tyne NE7 7DN, United Kingdom. Phone: 44-191-284-3111, ext. 26948; Fax: 44-191-213-0205; E-mail: F.C.Hamdy@ncl.ac.uk.

Received 3/31/97. Accepted 8/ 1/97.

This article has been cited by other articles:

				J. Dai, C. L. Hall, J. Escara-Wilke, A. Mizokami, J. M. Keller, and E. T. Keller Prostate Cancer Induces Bone Metastasis through Wnt-Induced Bone Morphogenetic Protein-Dependent and Independent Mechanisms Cancer Res., July 15, 2008; 68(14): 5785 - 5794. [Abstract] [Full Text] [PDF]

				S.-H. Lin, Y.-C. Lee, M. B. Choueiri, S. Wen, P. Mathew, X. Ye, K.-A. Do, N. M. Navone, J. Kim, S.-M. Tu, et al. Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer Clin. Cancer Res., June 15, 2008; 14(12): 3729 - 3736. [Abstract] [Full Text] [PDF]

				M. Daibata, Y. Nemoto, K. Bandobashi, N. Kotani, M. Kuroda, M. Tsuchiya, H. Okuda, T. Takakuwa, S. Imai, T. Shuin, et al. Promoter Hypermethylation of the Bone Morphogenetic Protein-6 Gene in Malignant Lymphoma Clin. Cancer Res., June 15, 2007; 13(12): 3528 - 3535. [Abstract] [Full Text] [PDF]

				B. L. Theriault, T. G. Shepherd, M. L. Mujoomdar, and M. W. Nachtigal BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells Carcinogenesis, June 1, 2007; 28(6): 1153 - 1162. [Abstract] [Full Text] [PDF]

				J. Dai, J. Keller, J. Zhang, Y. Lu, Z. Yao, and E. T. Keller Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases through a Dual Mechanism Cancer Res., September 15, 2005; 65(18): 8274 - 8285. [Abstract] [Full Text] [PDF]

				D. R. Haudenschild, S. M. Palmer, T. A. Moseley, Z. You, and A. H. Reddi Bone Morphogenetic Protein (BMP)-6 Signaling and BMP Antagonist Noggin in Prostate Cancer Cancer Res., November 15, 2004; 64(22): 8276 - 8284. [Abstract] [Full Text] [PDF]

				J. Dai, Y. Kitagawa, J. Zhang, Z. Yao, A. Mizokami, S. Cheng, J. Nor, L. K. McCauley, R. S. Taichman, and E. T. Keller Vascular Endothelial Growth Factor Contributes to the Prostate Cancer-Induced Osteoblast Differentiation Mediated by Bone Morphogenetic Protein Cancer Res., February 1, 2004; 64(3): 994 - 999. [Abstract] [Full Text] [PDF]

				T. G. Shepherd and M. W. Nachtigal Identification of a Putative Autocrine Bone Morphogenetic Protein-Signaling Pathway in Human Ovarian Surface Epithelium and Ovarian Cancer Cells Endocrinology, August 1, 2003; 144(8): 3306 - 3314. [Abstract] [Full Text] [PDF]

				O. Hjertner, H. Hjorth-Hansen, M. Borset, C. Seidel, A. Waage, and A. Sundan Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells Blood, January 15, 2001; 97(2): 516 - 522. [Abstract] [Full Text] [PDF]

				A. K. Heikinheimo, M. A. Laine, O. V-P. Ritvos, R. J. Voutilainen, B. L. M. Hogan, and I. V. Leivo Bone Morphogenetic Protein-6 Is a Marker of Serous Acinar Cell Differentiation in Normal and Neoplastic Human Salivary Gland Cancer Res., November 1, 1999; 59(22): 5815 - 5821. [Abstract] [Full Text] [PDF]